Abstract

For every movement, heartbeat and thought, ion channels need to open and close. It is therefore not surprising that their malfunctioning leads to serious diseases. Currently, only approximately 10% of drugs, with a market value in excess of US$10 billion, act on ion channels. The systematic exploitation of this target class has started, enabled by novel assay technologies and fundamental advances of the structural and mechanistic understanding of channel function. The latter, which was rewarded with the Nobel Prize in 2003, has opened up an avenue for rational drug design. In this review we provide an overview of the current repertoire of screening technologies that has evolved to drive ion channel-targeted drug discovery towards new medicines of the future.

Papers of special note have been highlighted as: ▪▪ of considerable interest

Bibliography

1 Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science291(5507),1304–1351 (2001).
Medline CASGoogle Scholar
2 Lehmann-Horn F, Rudel R, Dengler R, Lorkovic H, Haass A, Ricker K. Membrane defects in paramyotonia congenita with and without myotonia in a warm environment. Muscle Nerve4(5),396–406 (1981).
Medline CASGoogle Scholar
3 Schwartzkroin PA, Wyler AR. Mechanisms underlying epileptiform burst discharge. Ann. Neurol.7(2),95–107 (1980).
Medline CASGoogle Scholar
4 Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science245(4922),1066–1073 (1989).
Medline CASGoogle Scholar
5 Griggs RC, Nutt JG. Episodic ataxias as channelopathies. Ann. Neurol.37(3),285–287 (1995).
Medline CASGoogle Scholar
6 Ashcroft FM. From molecule to malady. Nature440(7083),440–447 (2006).
Medline CASGoogle Scholar
7 Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov.5(10),821–834 (2006).
Medline CASGoogle Scholar
8 Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch.391(2),85–100 (1981).
Medline CASGoogle Scholar
9 Bouevitch O, Lewis A, Pinevsky I, Wuskell JP, Loew LM. Probing membrane potential with nonlinear optics. Biophys. J.65(2),672–679 (1993).
Medline CASGoogle Scholar
10 Knisley SB, Blitchington TF, Hill BC et al. Optical measurements of transmembrane potential changes during electric field stimulation of ventricular cells. Circ. Res.72(2),255–270 (1993).
Medline CASGoogle Scholar
11 Epps DE, Wolfe ML, Groppi V. Characterization of the steady-state and dynamic fluorescence properties of the potential-sensitive dye bis-(1,3-dibutylbarbituric acid)trimethine oxonol (Dibac₄(3)) in model systems and cells. Chem. Phys. Lipids69(2),137–150 (1994).▪▪ Description of DiBAC4(3) as voltage sensor.
Medline CASGoogle Scholar
12 Schroeder KS, Neagle BD. FLiPR: a new instrument for accurate high-throughput optical screening. J. Biomol. Screen.1,75–80 (1996).▪▪ First paper describing the FLiPR platform for ion channel screening.
CASGoogle Scholar
13 Holevinsky KO, Fan Z, Frame M, Makielski JC, Groppi V, Nelson DJ. ATP-sensitive K⁺ channel opener acts as a potent Cl^- channel inhibitor in vascular smooth muscle cells. J. Membr. Biol.137(1),59–70 (1994).▪▪ First application of DiBAC4(3) for ion channel screening.
Medline CASGoogle Scholar
14 Dorn A, Hermann F, Ebneth A et al. Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition. J. Biomol. Screen.10(4),339–347 (2005).
Medline CASGoogle Scholar
15 Gopalakrishnan M, Molinari EJ, Shieh CC et al. Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K⁺ channel Kir6.2 combination expressed in HEK-293 cells. Br. J. Pharmacol.129(7),1323–1332 (2000).
Medline CASGoogle Scholar
16 Terstappen GC, Pellacani A, Aldegheri L et al. The antidepressant fluoxetine blocks the human small conductance calcium-activated potassium channels SK1, SK2 and SK3. Neurosci. Lett.346(1–2),85–88 (2003).
Medline CASGoogle Scholar
17 Whiteaker KL, Davis-Taber R, Scott VE, Gopalakrishnan M. Fluorescence-based functional assay for sarcolemmal ATP-sensitive potassium channel activation in cultured neonatal rat ventricular myocytes. J. Pharmacol. Toxicol. Methods46(1),45–50 (2001).
Medline CASGoogle Scholar
18 Whiteaker KL, Gopalakrishnan SM, Groebe D et al. Validation of FLiPR membrane potential dye for high throughput screening of potassium channel modulators. J. Biomol. Screen.6(5),305–312 (2001).
Medline CASGoogle Scholar
19 Vasilyev DV, Shan QJ, Lee YT et al. A novel high-throughput screening assay for HCN channel blocker using membrane potential-sensitive dye and FLiPR. J. Biomol. Screen.14(9),1119–1128 (2009).
Medline CASGoogle Scholar
20 Benjamin ER, Pruthi F, Olanrewaju S et al. State-dependent compound inhibition of Na_v1.2 sodium channels using the FLiPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J. Biomol. Screen.11(1),29–39 (2006).
Medline CASGoogle Scholar
21 Joesch C, Guevarra E, Parel SP et al. Use of FLiPR membrane potential dyes for validation of high-throughput screening with the FLiPR and microARCS technologies: identification of ion channel modulators acting on the GABA_A receptor. J. Biomol. Screen.13(3),218–228 (2008).
Medline CASGoogle Scholar
22 Slack M, Kirchhoff C, Moller C, Winkler D, Netzer R. Identification of novel K_v1.3 blockers using a fluorescent cell-based ion channel assay. J. Biomol. Screen.11(1),57–64 (2006).
Medline CASGoogle Scholar
23 Gonzalez JE, Tsien RY. Voltage sensing by fluorescence resonance energy transfer in single cells. Biophys. J.69(4),1272–1280 (1995).▪▪ Introduction of fluorescence resonance energy transfer (FRET) for voltage sensing.
Medline CASGoogle Scholar
24 Gonzalez JE, Tsien RY. Improved indicators of cell membrane potential that use fluorescence resonance energy transfer. Chem. Biol.4(4),269–277 (1997).
Medline CASGoogle Scholar
25 Falconer M, Smith F, Surah-Narwal S et al. High-throughput screening for ion channel modulators. J. Biomol. Screen.7(5),460–465 (2002).▪▪ First paper describing the ViPR® platform for FRET assays.
Medline CASGoogle Scholar
26 Felix JP, Williams BS, Priest BT et al. Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev. Technol.2(3),260–268 (2004).
Medline CASGoogle Scholar
27 Liu CJ, Priest BT, Bugianesi RM et al. A high-capacity membrane potential FRET-based assay for Na_V1.8 channels. Assay Drug Dev. Technol.4(1),37–48 (2006).
Medline CASGoogle Scholar
28 Solly K, Cassaday J, Felix JP et al. Miniaturization and HTS of a FRET-based membrane potential assay for K_ir channel inhibitors. Assay Drug Dev. Technol.6(2),225–234 (2008).
Medline CASGoogle Scholar
29 Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol. Pharmacol.25(2),228–234 (1984).
Medline CASGoogle Scholar
30 Rasmussen CA Jr, Sutko JL, Barry WH. Effects of ryanodine and caffeine on contractility, membrane voltage, and calcium exchange in cultured heart cells. Circ. Res.60(4),495–504 (1987).
Medline CASGoogle Scholar
31 Rasmussen H, Takuwa Y, Park S. Protein kinase C in the regulation of smooth muscle contraction. FASEB J.1(3),177–185 (1987).
Medline CASGoogle Scholar
32 Weir SW, Weston AH. The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on ⁸⁶Rb efflux in rat blood vessels. Br. J. Pharmacol.88(1),121–128 (1986).
Medline CASGoogle Scholar
33 Terstappen GC. Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. Anal. Biochem.272(2),149–155 (1999).▪▪ Introduction of atomic absorption spectroscopy for ion channel screening.
Medline CASGoogle Scholar
34 Terstappen GC. Nonradioactive rubidium ion efflux assay and its applications in drug discovery and development. Assay Drug Dev. Technol.2(5),553–559 (2004).
Medline CASGoogle Scholar
35 Terstappen GC. Nonradioactive rubidium efflux assay technology for screening of ion channels. In: Label-Free Assay Technologies for Drug Discovery. Cooper M, Mayer L (Eds). Wiley-VCH, Weinheim, Germany (2010) (In Press).
Google Scholar
36 Rezazadeh S, Hesketh JC, Fedida D. Rb⁺ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb⁺ efflux assay. J. Biomol. Screen.9(7),588–597 (2004).
Medline CASGoogle Scholar
37 Tang W, Kang J, Wu X et al. Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen.6(5),325–331 (2001).
Medline CASGoogle Scholar
38 Chaudhary KW, O’Neal JM, Mo ZL, Fermini B, Gallavan RH, Bahinski A. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade. Assay Drug Dev. Technol.4(1),73–82 (2006).
Medline CASGoogle Scholar
39 Trivedi S, Dekermendjian K, Julien R et al. Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators. Assay Drug Dev. Technol.6(2),167–179 (2008).
Medline CASGoogle Scholar
40 Gill S, Gill R, Xie Y, Wicks D, Liang D. Development and validation of HTS flux assay for endogenously expressed chloride channels in a CHO-K1 cell line. Assay Drug Dev. Technol.4(1),65–71 (2006).
Medline CASGoogle Scholar
41 Kasner SE, Ganz MB. Regulation of intracellular potassium in mesangial cells: a fluorescence analysis using the dye, PBFI. Am. J. Physiol.262(3 Pt 2),F462–467 (1992).
Medline CASGoogle Scholar
42 Minta A, Tsien RY. Fluorescent indicators for cytosolic sodium. J. Biol. Chem.264(32),19449–19457 (1989).
Medline CASGoogle Scholar
43 Verkman AS, Takla R, Sefton B, Basbaum C, Widdicombe JH. Quantitative fluorescence measurement of chloride transport mechanisms in phospholipid vesicles. Biochemistry28(10),4240–4244 (1989).
Medline CASGoogle Scholar
44 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J. Biol. Chem.260(6),3440–3450 (1985).▪▪ Description of Fura-2 as prototype of a new family of Ca2+ indicators.
Medline CASGoogle Scholar
45 Mattheakis LC, Savchenko A. Assay technologies for screening ion channel targets. Curr. Opin. Drug Discov. Devel.4(1),124–134 (2001).
Medline CASGoogle Scholar
46 Song Y, Buelow B, Perraud AL, Scharenberg AM. Development and validation of a cell-based high-throughput screening assay for TRPM2 channel modulators. J. Biomol. Screen.13(1),54–61 (2008).
Medline CASGoogle Scholar
47 Dai G, Haedo RJ, Warren VA et al. A high-throughput assay for evaluating state dependence and subtype selectivity of Ca_v2 calcium channel inhibitors. Assay Drug Dev. Technol.6(2),195–212 (2008).
Medline CASGoogle Scholar
48 Weaver CD, Harden D, Dworetzky SI, Robertson B, Knox RJ. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J. Biomol. Screen.9(8),671–677 (2004).
Medline CASGoogle Scholar
49 Titus SA, Beacham D, Shahane SA et al. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal. Biochem.394(1),30–38 (2009).
Medline CASGoogle Scholar
50 Kiss L, Bennett PB, Uebele VN et al. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev. Technol.1(1,2),127–135 (2003).
Medline CASGoogle Scholar
51 Schroeder K, Neagle B, Trezise DJ, Worley J. Ionworks HT: a new high-throughput electrophysiology measurement platform. J. Biomol. Screen.8(1),50–64 (2003).▪▪ First paper describing the IonWorks platform.
Medline CASGoogle Scholar
52 Finkel A, Wittel A, Yang N, Handran S, Hughes J, Costantin J. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J. Biomol. Screen.11(5),488–496 (2006).▪▪ First paper describing population patch clamp and IonWorks Quattro platforms.
Medline CASGoogle Scholar
53 Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat. Rev. Drug Discov.7(4),358–368 (2008).▪▪ Describes recent advances in automated high-throughput electrophysiological instrumentation.
Medline CASGoogle Scholar
54 Lu Q, An WF. Impact of novel screening technologies on ion channel drug discovery. Comb. Chem. High Throughput Screen.11(3),185–194 (2008).
Medline CASGoogle Scholar
55 Bridgland-Taylor MH, Hargreaves AC, Easter A et al. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J. Pharmacol. Toxicol. Methods54(2),189–199 (2006).
Medline CASGoogle Scholar
56 Sorota S, Zhang XS, Margulis M, Tucker K, Priestley T. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev. Technol.3(1),47–57 (2005).
Medline CASGoogle Scholar
57 John VH, Dale TJ, Hollands EC et al. Novel 384-well population patch clamp electrophysiology assays for Ca²⁺-activated K⁺ channels. J. Biomol. Screen.12(1),50–60 (2007).
Medline CASGoogle Scholar
58 Jow F, Shen R, Chanda P et al. Validation of a medium-throughput electrophysiological assay for KCNQ_2/3 channel enhancers using IonWorks HT. J. Biomol. Screen.12(8),1059–1067 (2007).
Medline CASGoogle Scholar
59 Xie X, Van Deusen AL, Vitko I et al. Validation of high throughput screening assays against three subtypes of Ca_v3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev. Technol.5(2),191–203 (2007).
Medline CASGoogle Scholar
60 Lee YT, Vasilyev DV, Shan QJ, Dunlop J, Mayer S, Bowlby MR. Novel pharmacological activity of loperamide and CP-339,818 on human HCN channels characterized with an automated electrophysiology assay. Eur. J. Pharmacol.581(1–2),97–104 (2008).
Medline CASGoogle Scholar
61 Harmer AR, Abi-Gerges N, Easter A et al. Optimisation and validation of a medium-throughput electrophysiology-based hNa_v1.5 assay using IonWorks. J. Pharmacol. Toxicol. Methods57(1),30–41 (2008).
Medline CASGoogle Scholar
62 Castle N, Printzenhoff D, Zellmer S, Antonio B, Wickenden A, Silvia C. Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb. Chem. High Throughput Screen.12(1),107–122 (2009).
Medline CASGoogle Scholar
63 Cox JJ, Reimann F, Nicholas AK et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature444(7121),894–898 (2006).
Medline CASGoogle Scholar
64 Goldberg YP, MacFarlane J, MacDonald ML et al. Loss-of-function mutations in the Na_v1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet.71(4),311–319 (2007).
Medline CASGoogle Scholar
65 Dunlop J, Bowlby M, Peri R et al. Ion channel screening. Comb. Chem. High Throughput Screen.11(7),514–522 (2008).
Medline CASGoogle Scholar
66 Clare JJ, Chen MX, Downie DL, Trezise DJ, Powell AJ. Use of planar array electrophysiology for the development of robust ion channel cell lines. Comb. Chem. High Throughput Screen.12(1),96–106 (2009).
Medline CASGoogle Scholar
67 Dubin AE, Nasser N, Rohrbacher J et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J. Biomol. Screen.10(2),168–181 (2005).
Medline CASGoogle Scholar
68 Ghetti A, Guia A, Xu J. Automated voltage-clamp technique. Methods Mol. Biol.403,59–69 (2007).
Medline CASGoogle Scholar
69 Asmild M, Oswald N, Krzywkowski KM et al. Upscaling and automation of electrophysiology: toward high throughput screening in ion channel drug discovery. Receptors Channels9(1),49–58 (2003).
Medline CASGoogle Scholar
70 Beck EJ, Hutchinson TL, Qin N, Flores CM, Liu Y. Development and validation of a secondary screening assay for TRPM8 antagonists using QPatch HT. Assay Drug Dev. Technol.
Google Scholar
71 Mathes C, Friis S, Finley M, Liu Y. QPatch: the missing link between HTS and ion channel drug discovery. Comb. Chem. High Throughput Screen.12(1),78–95 (2009).
Medline CASGoogle Scholar
72 McPate M, Lilley S, Gosling M, Friis S, Jacobsen RB, Tranter P. Evaluation of the QPatch HT and HTX systems as methods for ion channel screening. Biophys. J.98(3, Suppl. 1),340a (2010).
Google Scholar
73 Farre C, Stoelzle S, Haarmann C, George M, Bruggemann A, Fertig N. Automated ion channel screening: patch clamping made easy. Expert Opin. Ther. Targets11(4),557–565 (2007).
Medline CASGoogle Scholar
74 Brueggemann A, George M, Klau M et al. Ion channel drug discovery and research: the automated nano-patch-clamp technology. Curr. Drug Discov. Technol.1(1),91–96 (2004).
Medline CASGoogle Scholar
75 Bruggemann A, George M, Klau M et al. High quality ion channel analysis on a chip with the NPC technology. Assay Drug Dev. Technol.1(5),665–673 (2003).
Medline CASGoogle Scholar
76 Farre C, Haythornthwaite A, Haarmann C et al. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Comb. Chem. High Throughput Screen.12(1),24–37 (2009).
Medline CASGoogle Scholar
77 Balasubramanian B, Imredy JP, Kim D, Penniman J, Lagrutta A, Salata JJ. Optimization of Ca_v1.2 screening with an automated planar patch clamp platform. J. Pharmacol. Toxicol. Methods59(2),62–72 (2009).
Medline CASGoogle Scholar
78 Guo L, Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J. Pharmacol. Toxicol. Methods52(1),123–135 (2005).
Medline CASGoogle Scholar
79 Korsgaard MP, Strobaek D, Christophersen P. Automated planar electrode electrophysiology in drug discovery: examples of the use of QPatch in basic characterization and high content screening on Na_v, K(Ca)2.3, and K_v11.1 channels. Comb. Chem. High Throughput Screen12(1),51–63 (2009).
Medline CASGoogle Scholar
80 Kutchinsky J, Friis S, Asmild M et al. Characterization of potassium channel modulators with QPatch automated patch-clamp technology: system characteristics and performance. Assay Drug Dev. Technol.1(5),685–693 (2003).
Medline CASGoogle Scholar
81 Tao H, Santa Ana D, Guia A et al. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev. Technol.2(5),497–506 (2004).
Medline CASGoogle Scholar
82 Mo ZL, Faxel T, Yang YS, Gallavan R, Messing D, Bahinski A. Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress. J. Pharmacol. Toxicol. Methods60(1),39–44 (2009).
Medline CASGoogle Scholar
83 Ratliff KS, Petrov A, Eiermann GJ et al. An automated electrophysiology serum shift assay for K(V) channels. Assay Drug Dev. Technol.6(2),243–253 (2008).
Medline CASGoogle Scholar
84 Jones KA, Garbati N, Zhang H, Large CH. Automated patch clamping using the QPatch. Methods Mol. Biol.565,209–223 (2009).
Medline CASGoogle Scholar
85 Schroder RL, Friis S, Sunesen M, Mathes C, Willumsen NJ. Automated patch-clamp technique: increased throughput in functional characterization and in pharmacological screening of small-conductance Ca²⁺ release-activated Ca²⁺ channels. J. Biomol. Screen.13(7),638–647 (2008).
MedlineGoogle Scholar
86 Dunlop J, Roncarati R, Jow B et al.In vitro screening strategies for nicotinic receptor ligands. Biochem. Pharmacol.74(8),1172–1181 (2007).
Medline CASGoogle Scholar
87 Friis S, Mathes C, Sunesen M, Bowlby MR, Dunlop J. Characterization of compounds on nicotinic acetylcholine receptor α7 channels using higher throughput electrophysiology. J. Neurosci. Methods177(1),142–148 (2009).
Medline CASGoogle Scholar

Vol. 2, No. 5

Metrics

Downloaded 453 times

History

Published online 12 May 2010

Published in print May 2010

Information

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Screening technologies for ion channel drug discovery

Abstract

Bibliography